Review



pe-cy7-cd45.1 antibody  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher pe-cy7-cd45.1 antibody
    Pe Cy7 Cd45.1 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/pm39740209-144-11-19
    Average 90 stars, based on 1 article reviews
    pe-cy7-cd45.1 antibody - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Secretory MPP3 reinforce myeloid differentiation trajectory and amplify myeloid cell production
    Article Snippet: For donor-derived chimerism analyses in transplanted mice, blood cells were stained with Gr-1-eFluor450 (48-5931-82; eBioscience), Mac-1-PE-Cy7, B220-APC-eFluor780, CD3-eFluor660 (50-0032-82; eBioscience), Ter-119-PE-Cy5 (15-5921-83; eBioscience), CD45.1-PE (12-0453-83; eBioscience), and CD45.2-FITC (11-0454-85; eBioscience).

    Article Title: Dendritic cell sphingosine-1-phosphate lyase regulates thymic egress
    Article Snippet: Fluorochrome- or biotin-conjugated monoclonal antibodies, CD4-efluor 450 (clone RM4-5), CD4-FITC (clone RM4-4), CD8-FITC (clone 53-6.7), CD8-PE (clone 53-6.7), CD62L-PerCP-Cy5.5 (clone MEL-14), CD69-PE-Cy7 (clone H1.2F3), B220-APC (clone RA3-6B2), CD45.1-PE (clone A20), CD45.2-APC (clone 104), CD45RB-APC (clone C363.16A), and CD11c-biotin (clone N4118) were from eBioscience.

    Article Title: A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
    Article Snippet: Flow-cytometry antibodies included CD3e-PE, PD1-BV605, CD45-BV786 (BD-Biosciences), CD90.1-FITC, CD62L-PECy7, CD45.1-APC, CD45.1-PE (eBioscience), CD45.2-Alexa700, CD-8α-Percp-Cy5.5, CD4-FITC, CD103-APC, CD24-APCcy7 (Invitrogen), CD44-APCy7, CD4-BV421, F4/80-PercpCy5.5, CD39-PECy7, PDL1-PE, CD90.2-Alexa 700, MHCII-BV421, CD11b-BV650, Ly6C-BV711 (Biolegend), CD8α-PE-Texas-red (Life Technologies, Carlsbad, CA, USA).

    Article Title: Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo
    Article Snippet: Tert −/− recipients were euthanized at 8 and 16 weeks post-transplant and stained with the same antibodies used above for lineage (without anti-B220), IL-7Rα-BV421 (as above), B220-APC/Cy7 (Biolegend # 103,224), CD45.1-PE (ThermoFisher # 61–0453-82, 1/100), CD45.2-BV711 (Biolegend # 109,847), and PI.

    Article Title: The aged hematopoietic system promotes hippocampal‐dependent cognitive decline
    Article Snippet: Blood was stained with CD11b‐PE‐Cy7 (eBioscience), Gr1‐PB (eBioscience), B220 APC‐Cy7 (eBioscience), CD3 APC (eBioscience), and TER119‐PE‐Cy5 (eBioscience), CD45.1‐PE (eBioscience), and CD45.2‐FITC (eBioscience).

    Article Title: A comprehensive RNA editome reveals that edited Azin1 partners with DDX1 to enable hematopoietic stem cell differentiation
    Article Snippet: The following antibodies were used for PB staining: CD45.2-APC, CD45.1-PE, CD3e-PeCy7, B220-PerCP-Cy5.5, Mac1-APC-eFluor780, Gr-1-APC-eFluor780 (eBioscience, Inc., San Diego, CA, USA).

    Article Title: Endothelial-specific Gata3 expression is required for hematopoietic stem cell generation
    Article Snippet: Antibody stainings were performed 30min on ice in the dark, using the following antibodies: CD41-BV421 (1:100; Biolegend; cat# 133911), CD45-BV421 (1:100; Biolegend; cat# 103133), CD45-APC-Cy7 (1:100; BD Bioscience; cat# 561037), CD45-A700 (1:50; Biolegend; cat# 103128), CD45.1-PE (1:200; eBioscience; cat# 12-0453-82), CD45.2-A700 (1:200; Biolegend; cat# 109821), CD43-BV421 (1:100; BD Bioscience; cat# 752957), Ter119-V500 (1:100; BD Bioscience; cat# 562120), VEC-PE-Cy7 (1:100; Biolegend; cat# 138016), VEC-AF647 (1:100; BD Bioscience; cat# 562242), CD11b-PB (1:200; Biolegend; cat# 101224) and Gr1-PB (1:200; Biolegend; cat# 108429).

    Article Title: Endothelial-specific Gata3 expression is required for hematopoietic stem cell generation
    Article Snippet: Antibody stainings were performed 30min on ice in the dark, using the following antibodies: CD41-BV421 (1:100; Biolegend; cat# 133911), CD45-BV421 (1:100; Biolegend; cat# 103133), CD45-APC-Cy7 (1:100; BD Bioscience; cat# 561037), CD45-A700 (1:50; Biolegend; cat# 103128), CD45.1-PE (1:200; eBioscience; cat# 12-0453-82), CD45.2-A700 (1:200; Biolegend; cat# 109821), CD43-BV421 (1:100; BD Bioscience; cat# 752957), Ter119-V500 (1:100; BD Bioscience; cat# 562120), VEC-PE-Cy7 (1:100; Biolegend; cat# 138016), VEC-AF647 (1:100; BD Bioscience; cat# 562242), CD11b-PB (1:200; Biolegend; cat# 101224) and Gr1-PB (1:200; Biolegend; cat# 108429).



    Similar Products

    anti mouse cd45 1 pe  (Miltenyi Biotec)
    92
    Miltenyi Biotec anti mouse cd45 1 pe
    LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage <t>of</t> <t>CD45.1</t> (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
    Anti Mouse Cd45 1 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/CD45%2E1+Antibody%2C+anti-mouse/pmc13293935-5-0-4
    Average 92 stars, based on 1 article reviews
    anti mouse cd45 1 pe - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    pe-cy7-cd45.1 antibody  (Thermo Fisher)
    90
    Thermo Fisher pe-cy7-cd45.1 antibody
    LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage <t>of</t> <t>CD45.1</t> (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
    Pe Cy7 Cd45.1 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/pm39740209-144-11-19
    Average 90 stars, based on 1 article reviews
    pe-cy7-cd45.1 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pe cy7 cd45 1 antibody  (Thermo Fisher)
    96
    Thermo Fisher pe cy7 cd45 1 antibody
    LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage <t>of</t> <t>CD45.1</t> (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
    Pe Cy7 Cd45 1 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/Sorvall+MTX+150/pmc11848385-145-17-20
    Average 96 stars, based on 1 article reviews
    pe cy7 cd45 1 antibody - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    pe anti-mouse cd45.1 antibody  (Thermo Fisher)
    90
    Thermo Fisher pe anti-mouse cd45.1 antibody
    (A) Comparing T cell subsets in paired analyses from the CNS and BM leukaemia niche. Equal frequency of T cells per 100,000 leukaemia cells in either leukaemia niche, p=0.76. CD4+ T cells were lower, and CD8+ T cells were higher in proportion to total T cells in the CNS niche compared with the BM niche, p=0.01 and p=0.03, respectively. As a proportion of CD4+ T cells, T regulatory cells (CD3+ CD4+ CD25+ Foxp3+) were lower in the CNS niche compared with the BM niche, p=0.02. N=5 paired samples. (B) Higher proportion of CTLA4 positive T cells in the CNS than BM niche, N=5 paired samples, p=0.01. Higher proportion of PD-1 positive CD8+ T cells in the CNS than BM niche, N=5 paired samples, p<0.01. Reduced proportion of CD69 positive CD4+ T cells in the CNS than BM leukaemia niche, N=4 paired samples, p<0.02. (C) Equal frequency of NK cells per 100,000 leukaemia cells in either CNS and BM niche. The proportion of CD69+ NK cells was higher in the CNS leukaemia niche, p=0.01. N=6 paired samples. (D) Leukaemia-associated macrophage (LAM) cytospin image of whole CNS infiltrate stained with fluorescently labelled antibodies against cKit (yellow, leukaemia cell) and F4/80 (red, macrophage). (E) LAM <t>(CD45.1+</t> F4/80+ Ly6C/6G- CD11b+ IA/IE+) frequency per 100,000 leukaemia cells was higher in the CNS than BM niche. N = 6 paired samples, p=0.031. (F) MHC-II negative macrophages predominate in the CNS leukaemia niche. MHC-II negative macrophages were identified as the IA/IE- fraction of CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+/- cells and expressed as a percentage thereof. In age-matched (8-12 weeks old) untransplanted controls, there was no difference in the percentage of MHC-II negative macrophages by niche, n=8 paired samples, p=0.20. In the miR-128a overexpression model, macrophages were more likely to be MHC-II negative in the CNS niche, n=6 paired samples, p=0.02. (G) Comparison of GFP+ or ’actively phagocytic’ MHC-II positive and negative macrophages. MHC-II negative macrophages are less phagocytic in the CNS leukaemia niche. N=6 paired samples, p=0.01.
    Pe Anti Mouse Cd45.1 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/bio_rxiv__2024__12__03__626602-255-2-7
    Average 90 stars, based on 1 article reviews
    pe anti-mouse cd45.1 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pe anti-mouse cd45.1 antibody (clone a20, ebioscience, 12-0543-83)  (Thermo Fisher)
    90
    Thermo Fisher pe anti-mouse cd45.1 antibody (clone a20, ebioscience, 12-0543-83)
    (A) Comparing T cell subsets in paired analyses from the CNS and BM leukaemia niche. Equal frequency of T cells per 100,000 leukaemia cells in either leukaemia niche, p=0.76. CD4+ T cells were lower, and CD8+ T cells were higher in proportion to total T cells in the CNS niche compared with the BM niche, p=0.01 and p=0.03, respectively. As a proportion of CD4+ T cells, T regulatory cells (CD3+ CD4+ CD25+ Foxp3+) were lower in the CNS niche compared with the BM niche, p=0.02. N=5 paired samples. (B) Higher proportion of CTLA4 positive T cells in the CNS than BM niche, N=5 paired samples, p=0.01. Higher proportion of PD-1 positive CD8+ T cells in the CNS than BM niche, N=5 paired samples, p<0.01. Reduced proportion of CD69 positive CD4+ T cells in the CNS than BM leukaemia niche, N=4 paired samples, p<0.02. (C) Equal frequency of NK cells per 100,000 leukaemia cells in either CNS and BM niche. The proportion of CD69+ NK cells was higher in the CNS leukaemia niche, p=0.01. N=6 paired samples. (D) Leukaemia-associated macrophage (LAM) cytospin image of whole CNS infiltrate stained with fluorescently labelled antibodies against cKit (yellow, leukaemia cell) and F4/80 (red, macrophage). (E) LAM <t>(CD45.1+</t> F4/80+ Ly6C/6G- CD11b+ IA/IE+) frequency per 100,000 leukaemia cells was higher in the CNS than BM niche. N = 6 paired samples, p=0.031. (F) MHC-II negative macrophages predominate in the CNS leukaemia niche. MHC-II negative macrophages were identified as the IA/IE- fraction of CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+/- cells and expressed as a percentage thereof. In age-matched (8-12 weeks old) untransplanted controls, there was no difference in the percentage of MHC-II negative macrophages by niche, n=8 paired samples, p=0.20. In the miR-128a overexpression model, macrophages were more likely to be MHC-II negative in the CNS niche, n=6 paired samples, p=0.02. (G) Comparison of GFP+ or ’actively phagocytic’ MHC-II positive and negative macrophages. MHC-II negative macrophages are less phagocytic in the CNS leukaemia niche. N=6 paired samples, p=0.01.
    Pe Anti Mouse Cd45.1 Antibody (Clone A20, Ebioscience, 12 0543 83), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd45%2E1-pe+antibody/anti+cd45/bio_rxiv__2024__12__03__626602-256-1-10
    Average 90 stars, based on 1 article reviews
    pe anti-mouse cd45.1 antibody (clone a20, ebioscience, 12-0543-83) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.

    Journal: Cell Reports Medicine

    Article Title: Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich’s ataxia models

    doi: 10.1016/j.xcrm.2026.102803

    Figure Lengend Snippet: LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.

    Article Snippet: Anti-mouse CD45.1 PE , Miltenyi , Cat# 130-102-499; RRID:AB_2660704.

    Techniques: Transplantation Assay, Isolation, Transduction, Infection, Irradiation, Mass Spectrometry, Derivative Assay, Plasmid Preparation

    (A) Comparing T cell subsets in paired analyses from the CNS and BM leukaemia niche. Equal frequency of T cells per 100,000 leukaemia cells in either leukaemia niche, p=0.76. CD4+ T cells were lower, and CD8+ T cells were higher in proportion to total T cells in the CNS niche compared with the BM niche, p=0.01 and p=0.03, respectively. As a proportion of CD4+ T cells, T regulatory cells (CD3+ CD4+ CD25+ Foxp3+) were lower in the CNS niche compared with the BM niche, p=0.02. N=5 paired samples. (B) Higher proportion of CTLA4 positive T cells in the CNS than BM niche, N=5 paired samples, p=0.01. Higher proportion of PD-1 positive CD8+ T cells in the CNS than BM niche, N=5 paired samples, p<0.01. Reduced proportion of CD69 positive CD4+ T cells in the CNS than BM leukaemia niche, N=4 paired samples, p<0.02. (C) Equal frequency of NK cells per 100,000 leukaemia cells in either CNS and BM niche. The proportion of CD69+ NK cells was higher in the CNS leukaemia niche, p=0.01. N=6 paired samples. (D) Leukaemia-associated macrophage (LAM) cytospin image of whole CNS infiltrate stained with fluorescently labelled antibodies against cKit (yellow, leukaemia cell) and F4/80 (red, macrophage). (E) LAM (CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+) frequency per 100,000 leukaemia cells was higher in the CNS than BM niche. N = 6 paired samples, p=0.031. (F) MHC-II negative macrophages predominate in the CNS leukaemia niche. MHC-II negative macrophages were identified as the IA/IE- fraction of CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+/- cells and expressed as a percentage thereof. In age-matched (8-12 weeks old) untransplanted controls, there was no difference in the percentage of MHC-II negative macrophages by niche, n=8 paired samples, p=0.20. In the miR-128a overexpression model, macrophages were more likely to be MHC-II negative in the CNS niche, n=6 paired samples, p=0.02. (G) Comparison of GFP+ or ’actively phagocytic’ MHC-II positive and negative macrophages. MHC-II negative macrophages are less phagocytic in the CNS leukaemia niche. N=6 paired samples, p=0.01.

    Journal: bioRxiv

    Article Title: Leukaemia cell intrinsic and extrinsic factors cooperate to facilitate the survival and proliferation of KMT2A-rearranged B-ALL in the CNS niche

    doi: 10.1101/2024.12.03.626602

    Figure Lengend Snippet: (A) Comparing T cell subsets in paired analyses from the CNS and BM leukaemia niche. Equal frequency of T cells per 100,000 leukaemia cells in either leukaemia niche, p=0.76. CD4+ T cells were lower, and CD8+ T cells were higher in proportion to total T cells in the CNS niche compared with the BM niche, p=0.01 and p=0.03, respectively. As a proportion of CD4+ T cells, T regulatory cells (CD3+ CD4+ CD25+ Foxp3+) were lower in the CNS niche compared with the BM niche, p=0.02. N=5 paired samples. (B) Higher proportion of CTLA4 positive T cells in the CNS than BM niche, N=5 paired samples, p=0.01. Higher proportion of PD-1 positive CD8+ T cells in the CNS than BM niche, N=5 paired samples, p<0.01. Reduced proportion of CD69 positive CD4+ T cells in the CNS than BM leukaemia niche, N=4 paired samples, p<0.02. (C) Equal frequency of NK cells per 100,000 leukaemia cells in either CNS and BM niche. The proportion of CD69+ NK cells was higher in the CNS leukaemia niche, p=0.01. N=6 paired samples. (D) Leukaemia-associated macrophage (LAM) cytospin image of whole CNS infiltrate stained with fluorescently labelled antibodies against cKit (yellow, leukaemia cell) and F4/80 (red, macrophage). (E) LAM (CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+) frequency per 100,000 leukaemia cells was higher in the CNS than BM niche. N = 6 paired samples, p=0.031. (F) MHC-II negative macrophages predominate in the CNS leukaemia niche. MHC-II negative macrophages were identified as the IA/IE- fraction of CD45.1+ F4/80+ Ly6C/6G- CD11b+ IA/IE+/- cells and expressed as a percentage thereof. In age-matched (8-12 weeks old) untransplanted controls, there was no difference in the percentage of MHC-II negative macrophages by niche, n=8 paired samples, p=0.20. In the miR-128a overexpression model, macrophages were more likely to be MHC-II negative in the CNS niche, n=6 paired samples, p=0.02. (G) Comparison of GFP+ or ’actively phagocytic’ MHC-II positive and negative macrophages. MHC-II negative macrophages are less phagocytic in the CNS leukaemia niche. N=6 paired samples, p=0.01.

    Article Snippet: For macrophages: PE anti-mouse CD45.1 antibody (cloneA20, eBiosciences, 12-0543-83), BV711 anti-mouse Ly6C-G antibody (clone RB6-8CA, Biolegend, 108443), APC anti- mouse F4/80 antibody (clone BM8, Biolegend, 123115), PeCy7 anti-mouse I-A/I-E antibody (clone M5/114.15.2, Biolegend, 107629), BUV395 anti-mouse CD11b antibody (clone M1/70, BD Biosciences, 565976), DAPI (Life Tech, D1306).

    Techniques: Staining, Over Expression, Comparison